Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection

NCT02859961 is registered in ClinicalTrials.gov with CytoDyn, Inc. as lead sponsor.

NCT NCT02859961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02859961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection
Lead sponsor
CytoDyn, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
December 7, 2016
Completion date
December 7, 2020
Enrollment
562 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hiv